Stein Jeffrey, President & CEO, has demonstrated a clear selling bias in his insider transactions, with $17.6 million in total sales compared to $1.99 million in purchases across 31 reported trades. His most significant recent activity involved CDTX (Cidara Therapeutics), where he executed multiple dispositions in early January 2026, including a $14.95 million sale and two other transactions valued at $526,948 and $1.28 million. These disposals followed earlier activity in December 2025, including a $501,786 sale under code "F" (payment of exercise price or tax liability). The pattern shows Jeffrey has been reducing his CDTX position substantially after holding shares for several years, with his last purchase in the company dating back to November 2020 for $100,015.
More recently, Jeffrey shifted focus to IDYA (IDEAYA Biosciences), where he acquired shares worth $1.65 million on March 2, 2026—his only recent purchase. This marks a departure from his predominant selling trend and suggests a potential reallocation of holdings. The data reveals Jeffrey has been an active trader in the biotech sector, with his transactions concentrated in CDTX until early 2026 before pivoting to IDYA. His trading history shows a long-term engagement with CDTX, beginning with purchases as early as September 2017, followed by years of periodic sales culminating in the large-scale dispositions in early 2026.
AI-assisted summary